Mersana Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

February 27, 2017

CAMBRIDGE, Mass., February 27, 2017 -- Mersana Therapeutics, Inc., today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place in Boston on Monday, March 6, 2017, from 3:00 -3:25pm EST.

About Mersana Therapeutics                                                          

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients.  Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017.  In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.


Media Contact

Paul Kidwell

Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
(212) 362-1200